Business Standard

Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million

Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells

Logo of French drugmaker Sanofi | Photo: Reuters
Premium

Photo: Reuters

Reuters
Sanofi is offering to buy Dutch biotechnology company Kiadis for 308 million euros ($358.4 million) to boost its range of immunotherapy products.
 
The French drugmaker will offer 5.45 euros in cash, the companies said in a joint statement on Monday, a premium of 272% to Kiadis' closing share price on Oct. 30.
 
Shares in Kiadis, focused on cell-based immunotherapy products for the treatment of cancer, were up 245% in early trading. Sanofi shares were up 1.18%.
 
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells.
 
"We

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in